New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSyn-Coll vs SS-31 (Elamipretide)

Syn-Coll vs SS-31 (Elamipretide)

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Syn-Coll
Anti-Aging & Longevity
SS-31 (Elamipretide)
Summary
Syn-Coll is a palmitoylated tripeptide (Palmitoyl Tripeptide-5) that mimics thrombospondin-1 to activate TGF-beta, the primary growth factor driving collagen synthesis in the dermis. It is one of the most mechanistically direct collagen-stimulating peptides in cosmetic formulations.
SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
Half-Life
Extended (lipid depot in stratum corneum)
~2–5 hours
Admin Route
Topical
SubQ
Research
Typical Dose
0.005-0.05% in formulation
5–10 mg
Frequency
Once or twice daily
Daily to several times per week
Key Benefits
  • Directly activates TGF-beta for potent collagen synthesis stimulation
  • Increases dermal thickness and firmness
  • Reduces depth of wrinkles and fine lines
  • Improves skin elasticity
  • Clinically validated in collagen induction studies
  • Complementary to retinoids or vitamin C
  • Restores mitochondrial function and ATP production
  • Protects inner mitochondrial membrane cardiolipin
  • Reduces mitochondrial reactive oxygen species (ROS)
  • Improves exercise capacity and reduces fatigue
  • Cardioprotective — studied in heart failure trials
  • Renoprotective — reduces ischemic kidney injury
  • Anti-aging via mitochondrial preservation
  • Potential in neurodegenerative disease prevention
Side Effects
  • Generally well-tolerated
  • Rare mild irritation at high concentrations
  • Possible sensitivity in individuals with inflammatory skin conditions
  • Injection site irritation
  • Nausea (rare)
  • Generally well-tolerated in clinical trials
Stacks With